Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Epilepsy
- Healthy Volunteer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Suninflam Inc
- Last updated on ClinicalTrials.gov
- June 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Center for Neurosciences · Tucson, AZ
Florida · 3
- Accel Research sites network · DeLand, FL
- D&H Tamarac Research Center, LLC · Tamarac, FL
- Encore Medical Research of Weston, LLC · Weston, FL
Hawaii · 1
- Hawaii Pacific Neuroscience, Comprehensive Epilepsy Center · Honolulu, HI
Michigan · 1
- Quest Research Institute · Farmington Hills, MI
New York · 1
- Dent Neurologic Institute · Amherst, NY
North Carolina · 1
- OnSite Clinical Solutions, LLC · Charlotte, NC
Texas · 1
- Horizon Clinical Research Center · Cypress, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.